Clinical Trials Browser

Phase 3 × Interventional × Drug Therapy × Clear all

NCT07284394 2026-05-26

PACHA-02

Phase 3 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07419295 2026-05-22

TroFuse-031

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT03409614 2026-05-18

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Phase 3 Completed

789 enrolled 32 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT06724237 2026-05-15

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Phase 3 Recruiting

Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT03570892 2026-05-14

BELINDA

Phase 3 Completed

330 enrolled 10 charts

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Phase 3 Not yet recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT05340491 2026-05-11

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT05780372 2026-05-11

Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT05941741 2026-05-11

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT05673148 2026-05-08

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06578247 2026-04-30

QuANTUM-WILD

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT07556848 2026-04-30

A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06402708 2026-04-27

Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

Phase 3 Recruiting

Thymoma

NCT03710876 2026-04-21

INFINITE

Phase 3 Completed

53 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT07222800 2026-04-21

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Phase 3 Recruiting

Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Rectal Diseases, Colorectal Neoplasms

NCT05633602 2026-04-17

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06195709 2026-04-17

ECLECTIC

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04307277 2026-04-14

CHIC-STS01

Phase 3 Recruiting

Sarcoma

NCT07477808 2026-03-23

Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06731478 2026-03-16

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT04575935 2026-03-05

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04928807 2026-02-27

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)

Phase 3 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT03774732 2026-02-25

NIRVANA-LUNG

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07432087 2026-02-25

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT01013649 2026-02-23

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Phase 3 Completed

546 enrolled 29 charts

Gastrointestinal

Pancreatic Intraductal Neoplasms

NCT07022483 2026-02-04

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Phase 3 Recruiting

Neoplasms, Endometrial Neoplasms

NCT06627712 2026-01-30

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT06952621 2026-01-30

TD-NEOE3V3

Phase 3 Not yet recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05909332 2026-01-21

Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)

Phase 3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03875781 2026-01-15

NORAD01

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06899126 2026-01-08

DESTINY-Lung06

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05717166 2025-12-31

SABR-SYNC

Phase 3 Recruiting

Neoplasm Metastasis

NCT07306663 2025-12-29

ESO-Nanjing7

Phase 3 Active not recruiting

Gastrointestinal

Esophageal Neoplasms

NCT02314182 2025-12-19

GRECCAR8

Phase 3 Completed

Gastrointestinal

Rectal Neoplasms

NCT05111626 2025-12-15

FORTITUDE-102

Phase 3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT07262567 2025-12-03

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

Phase 3 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT02918955 2025-11-20

UPFRONT-NECK

Phase 3 Completed

Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Oropharyngeal Neoplasms

NCT05468489 2025-10-21

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Phase 3 Active not recruiting

Extensive Stage Small Cell Lung Cancer

NCT03721341 2025-09-18

SABR-COMET 10

Phase 3 Active not recruiting

Neoplasm Metastasis

NCT06840782 2025-09-15

OliGRAIL

Phase 3 Recruiting

Oligometastatic Non-small Cell Lung Cancer (NSCLC)

NCT03581786 2025-09-02

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Phase 3 Completed

289 enrolled 32 charts 1 FDA

Recurrence

NCT07135882 2025-08-22

PRIME-Lung

Phase 3 Not yet recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07062263 2025-07-14

TAB-2

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT06228079 2025-07-04

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT07027436 2025-06-18

DARTS

Phase 3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07020247 2025-06-13

Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study

Phase 3 Recruiting

Gastrointestinal

Locally Advanced Rectal Cancer (LARC)

NCT07016126 2025-06-11

D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06913777 2025-06-06

Neoadjuvant SNF Precision Therapy Phase III

Phase 3 Recruiting

Neoadjuvant Therapy

NCT07005557 2025-06-05

SENIOR

Phase 3 Not yet recruiting

Breast Neoplasms